Established in 1999, Sichuan Jiuzhang Biotech Co., Ltd. is engaged in the comprehensive research of natural active product screening, molecular structure transformation and related applications. It is a high-tech enterpriseintegrating scientific research, production and sales.
After long-term，in-depth pharmaceutical and clinical research, Jiuzhang has developed chlorogenic acid as a drug for the first time in the world and applied it to the treatment of major diseases (cancers). In 2013, it obtained the clinical approvals of raw medicine and chlorogenic acid injectionsregistered as Category 1 chemicals, that was issued by the CFDA(certificate numbers 2013L01856 and 2013L1855).
Jiuzhang has established a long-term and close strategic cooperative relationship with Institute of Materia Medica, Chinese Academy of Medical Sciences (IMM) in terms of system research and product development of chlorogenic acid, and has built a high-end R&D platform for chlorogenic acid and related products jointly. As two academic leaders of research on the pharmacological mechanism of chlorogenic acid, Professor Chen Xiaoguang, a famous pharmacological expert in China from IMM, and Professor Jiang Jiandong, a famous pharmaceutical expert, have carried out in-depth studies on the efficacy of chlorogenic acid and related preparations, the mechanism of action and other applications from both the immune and cellular levels respectively. Current studies have shown that chlorogenic acid and related preparations can play anti-tumor effects on both the immune and cellular levels, and display many characteristics such as multiple targets and channels. They are small novel natural molecular immune inhibitors that can induce the differentiation of tumor cells, thereby controlling the growth and metastasis of malignant tumors on both the immune and cellular levels, and prolonging the survival of patients. Moreover, the clinical trial of the chlorogenic acid for injectionas a novel drug in the treatment of malignant tumors shows that it demonstrates many characteristics such as high efficacy, broad spectrum of anti-tumor activities, low toxicity and no sensitization. It can be used in the treatment of tumors in early, middle and late stages, and shows an important value of clinical application and high safety . At present, chlorogenic acid for injection by Sichuan Jiuzhang Biotech Co., Ltd. is under the phase Ib clinical study.
Results of in-depth studies on immunomics and proteomics have shown that chlorogenic acid also yields significant responses in the treatment of some of the autoimmune diseases, including erythema psoriasis and systemic lupus erythematosus. Jiuzhang will continue to focus on in-depth studies on pharmacological mechanisms of chlorogenic acid and related preparations in the future, further the exploration of the potential applications in the treatment of various diseases, and develop more clinical needed products to benefit more patients.
As an enterprise committed to the development of China's own innovative drugs, Jiuzhang has established a strict intellectual property protection layout in the process of product development, providing a systematic and comprehensive patent protection in key applied fields, related derivatives, core processes and new dosage forms of chlorogenic acid. As of 2016, the company had applied for 104 international and domestic patents, of which 27 patents were secured (26 inventions and 1 utility model). Sichuan Jiuzhang Biotech Co., Ltd. has complete proprietary intellectual property rights over all the patents.
Since the establishment, Jiuzhang always abides by the research concept of “Respect for Nature” by conforming to objective laws. It has successfully explored a unique model for drug development, and has been committed to promoting harmonious coexistence between humans and the environment.